Introduction and Study Overview
Clinixir, Thailand’s leading Contract Research Organization (CRO), is pleased to share progress on a Phase II/III clinical trial investigating a potential immunotherapy for advanced hepatocellular carcinoma. This randomized, controlled study aims to enroll 150 patients across sites in Thailand and Malaysia. Clinixir’s role has focused on activating sites, coordinating patient recruitment, and supporting study milestones, advancing the trial’s success and contributing significantly to its overall progress. With nine clinical sites now active across both countries, enrollment is steadily progressing, with patient enrollment anticipated to conclude by mid-2025.
Progress Updates
Clinixir’s efficiency in site activation and patient recruitment has positioned Thailand as a leading contributor to the trial’s progress. All sites were operational in a short timeframe, enabling swift enrollment. The first patient was enrolled and received treatment shortly after site activation, reflecting Clinixir’s dedication to advancing the study according to the planned timeline. Recruitment is on track, with a substantial portion of the target patient enrollment achieved within the first year of the trial.
Positive Outcomes
The study is progressing well, with recruitment and enrollment advancing ahead of initial projections. Clinixir’s team has been instrumental in meeting milestones and ensuring a smooth patient experience. The active engagement and commitment of Principal Investigators (PIs), study sites, and our sponsor have been essential, driving rapid site activation, coordinated recruitment, and significant trial progress. Although specific results are not yet available, the progress thus far indicates a strong foundation for positive future outcomes.
Why Choose Clinixir?
Clinixir’s expertise and operational effectiveness have been instrumental in the trial’s success to date. Known for their strong relationships with clinical investigators, adherence to global best practices, and collaborative approach with study partners, Clinixir excels in site management, patient recruitment, and data quality. Key factors distinguishing Clinixir include:
- Efficient Site Activation and Management: Rapid setup of all trial sites ensured a quick transition to active recruitment.
- Collaborative Partnerships: Clinixir’s close collaboration with PIs, study sites, and the sponsor has been pivotal, enabling swift problem-solving and proactive trial support.
- Robust Patient Recruitment Strategies: Clinixir’s targeted recruitment methods and local expertise led to significant patient enrollment within the trial’s early stages.
- Commitment to High-Quality Data Collection: Clinixir’s processes prioritize high standards of data integrity, crucial for reliable trial outcomes.
As the study progresses, Clinixir’s focus remains on patient retention, protocol adherence, and timely achievement of trial milestones. This collaborative and proactive approach continues to set high standards for clinical research excellence in Thailand and beyond.
